BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35190936)

  • 1. A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.
    Laranjeira P; Rodrigues T; Silva A; Barbosa P; Reis T; Lopes C; Pinho A; Silva S; Silva I; Carvalho A; Pacheco V; Rodrigues F; Araújo L; Antunes I; Paiva A
    Clin Exp Med; 2023 Jun; 23(2):529-537. PubMed ID: 35190936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
    Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
    JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Response to SARS-CoV-2 Vaccine in 2 Men.
    Gupta S; Su H; Agrawal S
    Int Arch Allergy Immunol; 2022; 183(3):350-359. PubMed ID: 34794147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
    Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
    Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
    Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
    Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
    Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
    BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children.
    Ricciardi A; Zelini P; Cassaniti I; Avanzini MA; Colaneri M; De Silvestri A; Baldanti F; Bruno R
    Int J Infect Dis; 2022 Sep; 122():905-909. PubMed ID: 35803470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
    Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection.
    Casado JL; Vizcarra P; Martín-Hondarza A; Gómez-Maldonado S; Muedra-Sánchez M; Del Pino J; Mirabella IG; Martín-Colmenarejo S; Haemmerle J; Fernández-Escribano M; Vallejo A
    Front Immunol; 2023; 14():1127379. PubMed ID: 37457694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.